* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Posters – Infectious diseases and Vaccines NAME OF THE
Survey
Document related concepts
African trypanosomiasis wikipedia , lookup
Leptospirosis wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
Yellow fever wikipedia , lookup
Neglected tropical diseases wikipedia , lookup
Hepatitis C wikipedia , lookup
Influenza A virus wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
2015–16 Zika virus epidemic wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Ebola virus disease wikipedia , lookup
Orthohantavirus wikipedia , lookup
West Nile fever wikipedia , lookup
Hepatitis B wikipedia , lookup
Herpes simplex virus wikipedia , lookup
Transcript
Posters – Infectious diseases and Vaccines NAME OF THE PROJECT NAME OF THE MAIN CONTACT ORGANISATION NAME Dengue & Flaviviruses Rémi PICARD SATT Sud Est A new chemical family to treat tropical diseases induced by Dengue virus and other Flaviviruses: the hit compounds are non-nucleoside inhibitors active in vitro on a druggable target (RNA-dependent RNA polymerase (RdRP) NS5), protein of dengue flavivirus. The viral load will decrease by a short-term treatment. Technology This drug family is active against the 4 serotypes of DENV: knowing that immunization against one of the serotypes does not immunize against the 3 other ones and that all four serotypes (DENV-1 to 4) can cause the full spectrum of disease, this drug family addresses a major and actual concern. Screening platform: more than 17,000 compounds evaluated Better EC50 among the drug family = 12nM on DENV2 Applications: Antiviral therapy for Dengue Virus (in severe and lethal dengue hemorrhagic fevers), West Nile Virus,Yellow Fever Virus, Kunjin Virus and Japanese Encephalitis Virus. Customers / Target market Dengue is the most rapidly spreading mosquito-borne viral disease in the world. In the last 50 years, incidence has increased 30-fold. Over 2.5 billion people – over 40% of the world's population – are now at risk from dengue. There are around 30,000 deaths per year. To date, no antiviral treatment is available. Industry and competitors Chemical antiviral compounds could be used in human as: 1st line therapy for infected individuals, 1st line therapy for travelers (prophylactic), and 2nd line therapy in nonresponders to vaccination Financing need / Commercial opportunity We are currently looking for an industrial partner interested for licensing-in the technology and/or R&D collaboration (possible co-funding) IP – Patent situation Patent: PCT application (June 2014) Future steps / Milestones N/A Further reading N/A Contact person Elodie Dormes, Business [email protected] Development Manager, SATT Sud Est,